The Anti-diabetic Drug Gliquidone Modulates Lipopolysaccharide-Mediated Microglial Neuroinflammatory Responses by Inhibiting the NLRP3 Inflammasome

Ji‐Eun Kim, Jin-Hee Park, Keshvi Shah, Scott J. Mitchell, Kwangwook Cho, Hyang‐Sook HoeFrontiers in Aging Neuroscience 2021 · DOI

TL;DR

This study reveals that gliquidone, an anti-diabetic drug, can suppress neuroinflammation by targeting the NLRP3 inflammasome in microglia. This suggests a potential new therapeutic avenue for neuroinflammatory diseases, leveraging an existing drug.

What Problem Does This Paper Address?

Diabetes, particularly when poorly controlled, is linked to increased neuroinflammation in the brain. This chronic inflammation can contribute to various neurological issues, including brain atrophy and neuropathy. While some diabetes medications have shown promise in improving cognitive function and reducing dementia risk, the underlying mechanisms by which they affect neuroinflammation are not fully understood. This paper investigates whether gliquidone, a sulfonylurea drug used to treat type 2 diabetes, can modulate these neuroinflammatory responses, specifically focusing on its interaction with microglia and astrocytes, the primary immune cells of the brain.

Methods

The researchers employed a multi-pronged approach:

  • In vivo studies: Wild-type mice were treated with gliquidone (at doses of 10 or 20 mg/kg) or a vehicle, followed by an injection of lipopolysaccharide (LPS), a potent inducer of inflammation. Brain tissue was then analyzed using immunofluorescence staining to assess microglial (Iba-1) and astrocytic (GFAP) activation, as well as the expression of inflammatory markers like COX-2 and IL-6, and NLRP3 inflammasome components. Peripheral blood was also analyzed for inflammatory cytokines.
  • In vitro studies:
    • Cell culture: BV2 microglial cells and primary mouse astrocytes were used to investigate the molecular mechanisms.
  • Cytotoxicity assays: CCK and MTT assays were performed to determine safe concentrations of gliquidone for cell treatment.
  • Gene expression analysis: RT-PCR and quantitative PCR (q-PCR) were used to measure mRNA levels of inflammatory cytokines (IL-1β, IL-6, iNOS, COX-2), NLRP3, and SUR1.
  • Protein analysis: Western blotting was used to assess the phosphorylation status of key signaling molecules like ERK, STAT3, and NF-κB.
  • Immunocytochemistry (ICC): This technique was used to visualize the localization and expression of specific proteins within the cells.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from in vivo mouse models and in vitro cell cultures.

Key Insights and Ideas

  • Gliquidone as an anti-neuroinflammatory agent: The most significant finding is that gliquidone, an established anti-diabetic drug, can effectively suppress LPS-induced neuroinflammation. This opens up the possibility of repurposing existing drugs for neurological conditions.
  • Microglia as a primary target: Gliquidone appears to have a more pronounced effect on microglia than on astrocytes, significantly reducing microglial activation and hypertrophy. This suggests that microglia are a key cellular target for gliquidone's anti-inflammatory actions.
  • NLRP3 inflammasome inhibition: A crucial mechanism identified is gliquidone's ability to inhibit the LPS-induced activation of the NLRP3 inflammasome in microglia. This inflammasome is a critical mediator of inflammatory responses, and its suppression by gliquidone is a key takeaway.
  • Differential effects on astrocytes: While gliquidone does impact astrogliosis, its effects are less pronounced compared to microglia. It primarily affects STAT3/NF-κB signaling in astrocytes in an NLRP3-independent manner.
  • ERK/STAT3/NF-κB pathway modulation: In microglia, gliquidone's anti-inflammatory effects are linked to the inhibition of ERK, STAT3, and NF-κB phosphorylation, which are downstream signaling pathways activated by LPS.

Key Results

  • In vivo: Gliquidone treatment (especially at 20 mg/kg) significantly reduced LPS-induced microgliosis (Iba-1 staining) and astrogliosis (GFAP staining) in the cortex and hippocampus. It also significantly decreased the levels of the pro-inflammatory cytokines COX-2 and IL-6 in the brain. Furthermore, gliquidone treatment significantly reduced LPS-induced NLRP3 inflammasome activation in the brain and also reduced peripheral inflammatory cytokine levels (IL-1β and IL-6) in blood.
  • In vitro (BV2 microglia): Gliquidone did not exhibit cytotoxicity at concentrations up to 25 µM. It significantly reduced LPS-induced pro-inflammatory cytokine mRNA levels (IL-1β, IL-6, iNOS, COX-2) and protein levels. Gliquidone also suppressed LPS-induced phosphorylation of ERK, STAT3, and NF-κB. Crucially, gliquidone inhibited LPS-stimulated NLRP3 and pro-IL-1β mRNA and protein levels.
  • In vitro (Primary astrocytes): Gliquidone significantly reduced LPS-induced IL-1β and IL-6 mRNA levels but had less impact on iNOS and COX-2. It also decreased LPS-induced STAT3 and NF-κB phosphorylation in astrocytes, but this effect was independent of NLRP3 inflammasome activation.

Limitations and Future Work

  • Brain region specificity: The study noted that gliquidone's effects on Iba-1 and COX-2 were more pronounced in certain brain regions (cortex, hippocampus CA1/CA3) than others (DG region). The authors suggest that this might be due to region-specific expression of the target receptor subunits (SUR1 or Kir6) or K-ATP channels. Future work should investigate this differential expression and its impact on LPS-induced responses.
  • Duration of treatment: The study used a 3-day treatment protocol. The authors suggest that longer treatment durations (e.g., 7 or 14 days) might be necessary to observe effects in all brain regions and should be explored.
  • Mechanism of action refinement: While gliquidone's effects on ERK/STAT3/NF-κB and NLRP3 are shown, the authors suggest further investigation into other MAPK signaling pathways and transcription factors. Additionally, exploring the specific role of SUR1 versus other K-ATP channel subunits (Kir 6.1, Kir 6.2) in gliquidone's action would be valuable.
  • Therapeutic potential: The study highlights gliquidone's potential for treating neuroinflammation-associated diseases. Future research could focus on translating these findings into clinical applications, perhaps by investigating its efficacy in specific neurodegenerative disease models.

Summary updated

Abstract

The sulfonylurea drug gliquidone is FDA approved for the treatment of type 2 diabetes. Binding of gliquidone to ATP-sensitive potassium channels (SUR1, Kir6 subunit) in pancreatic β-cells increases insulin release to regulate blood glucose levels. Diabetes has been associated with increased levels of neuroinflammation, and therefore the potential effects of gliquidone on micro- and astroglial neuroinflammatory responses in the brain are of interest. Here, we found that gliquidone suppressed LPS-mediated microgliosis, microglial hypertrophy, and proinflammatory cytokine COX-2 and IL-6 levels in wild-type mice, with smaller effects on astrogliosis. Importantly, gliquidone downregulated the LPS-induced microglial NLRP3 inflammasome and peripheral inflammation in wild-type mice. An investigation of the molecular mechanism of the effects of gliquidone on LPS-stimulated proinflammatory responses showed that in BV2 microglial cells, gliquidone significantly decreased LPS-induced proinflammatory cytokine levels and inhibited ERK/STAT3/NF-κB phosphorylation by altering NLRP3 inflammasome activation. In primary astrocytes, gliquidone selectively affected LPS-mediated proinflammatory cytokine expression and decreased STAT3/NF-κB signaling in an NLRP3-independent manner. These results indicate that gliquidone differentially modulates LPS-induced microglial and astroglial neuroinflammation in BV2 microglial cells, primary astrocytes, and a model of neuroinflammatory disease.
BibTeX
@inproceedings{kim2021anti,
  author = {Ji‐Eun Kim and Jin-Hee Park and Keshvi Shah and Scott J. Mitchell and Kwangwook Cho and Hyang‐Sook Hoe},
  title = {{The Anti-diabetic Drug Gliquidone Modulates Lipopolysaccharide-Mediated Microglial Neuroinflammatory Responses by Inhibiting the NLRP3 Inflammasome}},
  booktitle = {Frontiers in Aging Neuroscience},
  year = {2021},
  doi = {10.3389/fnagi.2021.754123},
}
Figure